Boston posts May Taxus stent sales:
This article was originally published in Clinica
Executive Summary
Boston Scientific claims it still holds more than 70% of the US drug-eluting stent market after reporting revenues from its Taxus Express2 stent of $157m in the US and $201m worldwide for 20 selling days in May. The paclitaxel-coated coronary stent was launched in early March this year following FDA approval and has significantly boosted first-quarter results for the Natick, Masachusettes-based company (see Clinica No 1104, p20). April sales figures for the Taxus system were $163m in the US and $205m worldwide. The company estimates that approximately 75% of total stent placements now involve drug-eluting stents.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.